For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| Kai-Min Chu |
Kai-Min Chu |
Kai-Min Chu |
02-27885365 |
C516, Building C, No.99, Lane 130, Sec.1, Academia Rd., Nangang Dist.Taipei City 115, Taiwan(R.O.C.) |
2017/06/29 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
SINEW has six major products in two applications on hepatotoxicity-free acetaminophen (AAP) and fatty liver disease. SINEW, established in Taipei, Taiwan in 2014, is a new biopharmaceutical company with a focus on integrated new drug R&D.
The breakthrough hepatotoxicity-free AAP product (that produces minimal toxic metabolite) and an antidote for AAP overdose can help solve the long-standing problem caused by chronic and/or incidentally AAP overdose-induced acute liver failure or even death over the past 30 years. Besides, we have developed a new safe product that may effectively treat fatty liver disease or steatohepatitis, for which there is no standard treatment yet. In the pipeline, we also have new chemical entities and new combos at the stage of preclinical research.
At SINEW, our vision is to (1) become a world-class, innovation-based biopharmaceutical company, (2) comfort patient and (3) promote human health. |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
